Down-regulation of Cytokine-induced Interleukin-8 Requires Inhibition of P38 Mitogen-activated Protein Kinase (MAPK) Via MAPK Phosphatase 1-dependent and -independent Mechanisms

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2011 Apr 2

PMID 21454676

Citations 17

Authors

Nurlan Dauletbaev

Daniel Eklove

Nadir Mawji

Michele Iskandar

Sergio Di Marco

Imed-Eddine Gallouzi

Larry C Lands

Affiliations

Soon will be listed here.

Abstract

Down-regulation of overabundant interleukin (IL)-8 present in cystic fibrosis (CF) airways could ease excessive neutrophil burden and its deleterious consequences for the lung. IL-8 production in airway epithelial cells, stimulated with e.g. inflammatory cytokines IL-1β and tumor necrosis factor (TNF)-α, is regulated by several signaling pathways including nuclear factor (NF)-κB and p38 mitogen-activated protein kinase (MAPK). We previously demonstrated that the anti-inflammatory drugs dexamethasone and ibuprofen suppress NF-κB; however, only dexamethasone down-regulates cytokine-induced IL-8, highlighting the importance of non-NF-κB mechanisms. Here, we tested the hypothesis that down-regulation of cytokine-induced IL-8 requires modulation of the MAPK phosphatase (MKP)-1/p38 MAPK/mRNA stability pathway. The effects of dexamethasone (5 nm) and ibuprofen (480 μm) on this pathway and IL-8 were studied in CF (CFTE29o-, CFBE41o-) and non-CF (1HAEo-) airway epithelial cells. We observed that dexamethasone, but not ibuprofen, destabilizes IL-8 mRNA and up-regulates MKP-1 mRNA. Further, siRNA silencing of MKP-1, via p38 MAPK, leads to IL-8 overproduction and diminishes the anti-IL-8 potential of dexamethasone. However, MKP-1 overexpression does not significantly alter IL-8 production. By contrast, direct inhibition of p38 MAPK (inhibitor SB203580) efficiently suppresses IL-8 with potency comparable with dexamethasone. Similar to dexamethasone, SB203580 decreases IL-8 mRNA stability. Dexamethasone does not affect p38 MAPK activation, which excludes its effects upstream of p38 MAPK. In conclusion, normal levels of MKP-1 are necessary for a full anti-IL-8 potential of pharmacological agents; however, efficient pharmacological down-regulation of cytokine-induced IL-8 also requires direct effects on p38 MAPK and mRNA stability independently of MKP-1.

Citing Articles

Synergistic Inhibitory Effect of Lactobacillus Cell Lysates and Butyrate on Poly I:C-Induced IL-8 Production in Human Intestinal Epithelial Cells.

Park S, Choi Y, Gho J, Kang G, Kang S Probiotics Antimicrob Proteins. 2023; 16(1):1-12.

PMID: 36720771 DOI: 10.1007/s12602-023-10042-0.

Controlled Human Malaria Infection Induces Long-Term Functional Changes in Monocytes.

Walk J, Keramati F, de Bree L, Arts R, Blok B, Netea M Front Mol Biosci. 2020; 7:604553.

PMID: 33324683 PMC: 7726436. DOI: 10.3389/fmolb.2020.604553.

Preventing the development of severe COVID-19 by modifying immunothrombosis.

Morris G, Bortolasci C, Puri B, Olive L, Marx W, ONeil A Life Sci. 2020; 264:118617.

PMID: 33096114 PMC: 7574725. DOI: 10.1016/j.lfs.2020.118617.

Depletion of HuR in murine skeletal muscle enhances exercise endurance and prevents cancer-induced muscle atrophy.

Sanchez B, Tremblay A, Leduc-Gaudet J, Hall D, Kovacs E, Ma J Nat Commun. 2019; 10(1):4171.

PMID: 31519904 PMC: 6744452. DOI: 10.1038/s41467-019-12186-6.

eIF4A inhibition prevents the onset of cytokine-induced muscle wasting by blocking the STAT3 and iNOS pathways.

Cramer Z, Sadek J, Vazquez G, Di Marco S, Pause A, Pelletier J Sci Rep. 2018; 8(1):8414.

PMID: 29849089 PMC: 5976662. DOI: 10.1038/s41598-018-26625-9.

References

Gruenert D, Willems M, Cassiman J, Frizzell R . Established cell lines used in cystic fibrosis research. J Cyst Fibros. 2004; 3 Suppl 2:191-6. DOI: 10.1016/j.jcf.2004.05.040. View

Chmiel J, Berger M, Konstan M . The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol. 2002; 23(1):5-27. DOI: 10.1385/CRIAI:23:1:005. View

Konstan M, Byard P, Hoppel C, DAVIS P . Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med. 1995; 332(13):848-54. DOI: 10.1056/NEJM199503303321303. View

Elizur A, Cannon C, Ferkol T . Airway inflammation in cystic fibrosis. Chest. 2008; 133(2):489-95. DOI: 10.1378/chest.07-1631. View

Xu Y, Krause A, Hamai H, Harvey B, Worgall T, Worgall S . Proinflammatory phenotype and increased caveolin-1 in alveolar macrophages with silenced CFTR mRNA. PLoS One. 2010; 5(6):e11004. PMC: 2882373. DOI: 10.1371/journal.pone.0011004. View

Liu Y, Shepherd E, Nelin L . MAPK phosphatases--regulating the immune response. Nat Rev Immunol. 2007; 7(3):202-12. DOI: 10.1038/nri2035. View

Lands L, Stanojevic S . Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis. Cochrane Database Syst Rev. 2007; (4):CD001505. DOI: 10.1002/14651858.CD001505.pub2. View

Dauletbaev N, Lam J, Eklove D, Iskandar M, Lands L . Ibuprofen modulates NF-kB activity but not IL-8 production in cystic fibrosis respiratory epithelial cells. Respiration. 2009; 79(3):234-42. DOI: 10.1159/000255342. View

Bonfield T, Panuska J, Konstan M, Hilliard K, Hilliard J, Ghnaim H . Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med. 1995; 152(6 Pt 1):2111-8. DOI: 10.1164/ajrccm.152.6.8520783. View

10.

Armstrong D, Hook S, Jamsen K, Nixon G, Carzino R, Carlin J . Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr Pulmonol. 2005; 40(6):500-10. DOI: 10.1002/ppul.20294. View

11.

Kunzelmann K, Schwiebert E, Zeitlin P, Kuo W, Stanton B, Gruenert D . An immortalized cystic fibrosis tracheal epithelial cell line homozygous for the delta F508 CFTR mutation. Am J Respir Cell Mol Biol. 1993; 8(5):522-9. DOI: 10.1165/ajrcmb/8.5.522. View

12.

Patterson K, Brummer T, OBrien P, Daly R . Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J. 2009; 418(3):475-89. DOI: 10.1042/bj20082234. View

13.

Taggart C, Coakley R, Greally P, Canny G, ONeill S, McElvaney N . Increased elastase release by CF neutrophils is mediated by tumor necrosis factor-alpha and interleukin-8. Am J Physiol Lung Cell Mol Physiol. 2000; 278(1):L33-41. DOI: 10.1152/ajplung.2000.278.1.L33. View

14.

Lands L, Milner R, Cantin A, Manson D, Corey M . High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr. 2007; 151(3):249-54. DOI: 10.1016/j.jpeds.2007.04.009. View

15.

Sutherland E, Goleva E, Jackson L, Stevens A, Leung D . Vitamin D levels, lung function, and steroid response in adult asthma. Am J Respir Crit Care Med. 2010; 181(7):699-704. PMC: 2868500. DOI: 10.1164/rccm.200911-1710OC. View

16.

Rottner M, Freyssinet J, Martinez M . Mechanisms of the noxious inflammatory cycle in cystic fibrosis. Respir Res. 2009; 10:23. PMC: 2660284. DOI: 10.1186/1465-9921-10-23. View

17.

Konstan M . Ibuprofen therapy for cystic fibrosis lung disease: revisited. Curr Opin Pulm Med. 2008; 14(6):567-73. DOI: 10.1097/MCP.0b013e32831311e8. View

18.

Balough K, McCubbin M, Weinberger M, Smits W, Ahrens R, Fick R . The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol. 1995; 20(2):63-70. DOI: 10.1002/ppul.1950200203. View

19.

Lands L, Dauletbaev N . High-Dose Ibuprofen in Cystic Fibrosis. Pharmaceuticals (Basel). 2016; 3(7):2213-2224. PMC: 4036659. DOI: 10.3390/ph3072213. View

20.

Noah T, Black H, Cheng P, Wood R, Leigh M . Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis. J Infect Dis. 1997; 175(3):638-47. DOI: 10.1093/infdis/175.3.638. View